Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the…
Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center…
Martin Fischer, PhD, associate research professor in the department of chemistry at Duke Trinity College of Arts and Sciences, was tasked with examining the particle-blocking abilities of various…
Guidelines from the American Society of Hematology (ASH) review panel recommend standards of care for individualized acute myeloid leukemia (AML) treatments. For patients with newly diagnosed AML, ASH…
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for…
The American Society of Hematology (ASH) has released 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults. Specifically, the guidelines help patients and doctors…
Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation…
Carlos Del Rio, MD, Executive Associate Dean at Emory School of Medicine & Grady Health System, breaks down the four phases of clinical trials and discusses how the…
Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center – James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved…
Eunice Wang, MD, chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, discusses the outlook of acute myeloid leukemia (AML) treatment in the wake of…
